Clinical trial
Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the…
NCT00106561 · Melbourne Health, Other · Completed
Key facts
| NCT number | NCT00106561 |
|---|---|
| Title | Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney |
| Official title | A Double-Blind, Placebo-Controlled Study on the Effect of Spironolactone, in Patients With Persistent Proteinuria on Long-Term Angiotensin Converting Enzyme Inhibitor Therapy, With or With Out an Angiotensin II Receptor Blocker |
| Lead sponsor | Melbourne Health, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Kidney Disease, Diabetic Nephropathy, Glomerulonephritis, Proteinuria |
| Intervention type | Drug |
| Interventions | Spironolactone, Irbesartan |
| Enrollment | 60 |
| Start date | Jan 1, 2002 |
| Completion | Sep 1, 2004 |
| First posted | Mar 28, 2005 |
| Last update posted | Jun 24, 2005 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: